3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings, in CNY as reported — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | CN¥34M | -CN¥13M | 2.8% | -43.1% | -28.4% | -18.8% | — | — | CN¥1M |
| 2024 | CN¥88M | -CN¥1M | 6.2% | -0.0% | 17.9% | -2.3% | — | — | CN¥130923 |
| 2023 | CN¥83M | -CN¥993937 | 5.1% | 0.7% | 17.0% | — | — | — | CN¥591874 |
How the market has priced PASW against its own fundamentals since 2025-10 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 2 years, Ping An Biomedical Co., Ltd.'s revenue has declined 35.7% per year. These are computed facts, not advice.
As of FY2025, Ping An Biomedical Co., Ltd. reported — of total debt against CN¥1M of cash; operating income covered interest expense -47.9×.
In FY2025, gross margin was 2.8%, operating margin -43.1%, and net margin -37.6%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — its annual and interim reports, in CNY as reported (valuation multiples convert at the Federal Reserve H.10 rate of each date, via FRED) (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (annual and interim filings, reported in CNY) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · FX: Federal Reserve H.10 via FRED (DEXCHUS; 1 CNY = 0.1503 USD on 2026-10-30), the rate of each date for the valuation history · This product uses the FRED® API but is not endorsed or certified by the Federal Reserve Bank of St. Louis. · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.